Results from the phase III KEYNOTE-826 trial demonstrate that Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab improved disease outcomes when compared to chemotherapy with or without bevacizumab as a first-line treatment of persistent, recurrent, or metastatic cervical cancer.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
